VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients
| Autor: | Wouter B, Nagengast, Marjolijn N Lub-de, Hooge, Esther M E, van Straten, Schelto, Kruijff, Adrienne H, Brouwers, Wilfred F A, den Dunnen, Johan R, de Jong, Harry, Hollema, Rudi A, Dierckx, Nanno H, Mulder, Elisabeth G E, de Vries, Harald J, Hoekstra, Geke A P, Hospers |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Tomography Emission-Computed Single-Photon Vascular Endothelial Growth Factor A Time Factors Indium Radioisotopes Angiogenesis Inhibitors Middle Aged Antibodies Monoclonal Humanized Immunohistochemistry Bevacizumab Image Processing Computer-Assisted Humans Female Neoplasm Metastasis Infusions Intravenous Melanoma |
| Zdroj: | European journal of cancer (Oxford, England : 1990). 47(10) |
| ISSN: | 1879-0852 |
| Popis: | A feasibility study was performed to investigate the presence of VEGF in melanoma lesions by VEGF-SPECT with (111)In-bevacizumab. In addition the effect of a single therapeutic bevacizumab dose on (111)In-bevacizumab uptake was compared with VEGF levels in resected melanoma lesions.Eligible were patients with stage III/IV melanoma who presented with nodal recurrent disease. VEGF-SPECT was performed after administration of 100 Mbq (111)In-bevacizumab (8 mg) at days 0, 2, 4 and 7 post injection. Tumour visualisation and quantification were compared with CT and FDG-PET. On day 7 a single dose of 7.5mg/kg bevacizumab was administered intravenously. On day 21, a second tracer dose (111)In-bevacizumab was administered and scans were obtained on days 21, 25 and 28. Metastases were surgically resected within 2 weeks after the last VEGF-SPECT scan and immunohistological (IHC) VEGF tumour expression was compared with (111)In-bevacizumab tumour uptake.Nine patients were included. FDG-PET and CT detected both in total 12 nodal lesions which were all visualised by VEGF-SPECT. At baseline, (111)In-bevacizumab tumour uptake varied 3-fold between and 1.6 ± 0.1-fold within patients. After a therapeutic dose of bevacizumab there was a 21 ± 4% reduction in (111)In-bevacizumab uptake. The (111)In-bevacizumab tumour uptake in the second series positively correlated with the VEGF-A expression in the resected tumour lesions.VEGF-SPECT could visualise all known melanoma lesions. A single dose of bevacizumab slightly lowered (111)In-bevacizumab uptake. Future studies should elucidate the role of VEGF-SPECT in the selection of patients and the individual dosing of bevacizumab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect